Roberts D, Dalziel S
Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, Merseyside, UK L8 7SS.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD004454. doi: 10.1002/14651858.CD004454.pub2.
Respiratory distress syndrome (RDS) is a serious complication of preterm birth and the primary cause of early neonatal mortality and disability.
To assess the effects on fetal and neonatal morbidity and mortality, on maternal mortality and morbidity, and on the child in later life of administering corticosteroids to the mother before anticipated preterm birth.
We searched the Cochrane Pregnancy and Childbirth Group Trials Register (30 October 2005).
Randomised controlled comparisons of antenatal corticosteroid administration (betamethasone, dexamethasone, or hydrocortisone) with placebo or with no treatment given to women with a singleton or multiple pregnancy, expected to deliver preterm as a result of either spontaneous preterm labour, preterm prelabour rupture of the membranes or elective preterm delivery.
Two review authors assessed trial quality and extracted data independently.
Twenty-one studies (3885 women and 4269 infants) are included. Treatment with antenatal corticosteroids does not increase risk to the mother of death, chorioamnionitis or puerperal sepsis. Treatment with antenatal corticosteroids is associated with an overall reduction in neonatal death (relative risk (RR) 0.69, 95% confidence interval (CI) 0.58 to 0.81, 18 studies, 3956 infants), RDS (RR 0.66, 95% CI 0.59 to 0.73, 21 studies, 4038 infants), cerebroventricular haemorrhage (RR 0.54, 95% CI 0.43 to 0.69, 13 studies, 2872 infants), necrotising enterocolitis (RR 0.46, 95% CI 0.29 to 0.74, eight studies, 1675 infants), respiratory support, intensive care admissions (RR 0.80, 95% CI 0.65 to 0.99, two studies, 277 infants) and systemic infections in the first 48 hours of life (RR 0.56, 95% CI 0.38 to 0.85, five studies, 1319 infants). Antenatal corticosteroid use is effective in women with premature rupture of membranes and pregnancy related hypertension syndromes.
AUTHORS' CONCLUSIONS: The evidence from this new review supports the continued use of a single course of antenatal corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth. A single course of antenatal corticosteroids should be considered routine for preterm delivery with few exceptions. Further information is required concerning optimal dose to delivery interval, optimal corticosteroid to use, effects in multiple pregnancies, and to confirm the long-term effects into adulthood.
呼吸窘迫综合征(RDS)是早产的一种严重并发症,也是早期新生儿死亡和残疾的主要原因。
评估在预期早产前给母亲使用皮质类固醇对胎儿和新生儿发病率及死亡率、对母亲死亡率和发病率以及对儿童后期生活的影响。
我们检索了Cochrane妊娠与分娩组试验注册库(2005年10月30日)。
对单胎或多胎妊娠、因自发性早产、临产前胎膜早破或选择性早产而预期早产的妇女,进行产前皮质类固醇(倍他米松、地塞米松或氢化可的松)与安慰剂或不治疗的随机对照比较。
两位综述作者独立评估试验质量并提取数据。
纳入21项研究(3885名妇女和4269名婴儿)。产前使用皮质类固醇不会增加母亲死亡、绒毛膜羊膜炎或产褥期败血症的风险。产前使用皮质类固醇与新生儿死亡总体减少相关(相对危险度(RR)0.69,95%置信区间(CI)0.58至0.81,18项研究,3956名婴儿)、呼吸窘迫综合征(RR 0.66,95%CI 0.59至0.73,21项研究,4038名婴儿)、脑室内出血(RR 0.54,95%CI 0.43至0.69,13项研究,2872名婴儿)、坏死性小肠结肠炎(RR 0.46,95%CI 0.29至0.74,8项研究,1675名婴儿)、呼吸支持、重症监护入院(RR 0.80,95%CI 0.65至0.99,2项研究,277名婴儿)以及出生后48小时内的全身感染(RR 0.56,95%CI 0.38至0.85,5项研究,1319名婴儿)。产前使用皮质类固醇对胎膜早破和妊娠相关高血压综合征的妇女有效。
这项新综述的证据支持继续使用单疗程产前皮质类固醇来加速有早产风险妇女的胎儿肺成熟。除少数例外情况外,单疗程产前皮质类固醇应被视为早产分娩的常规用药。需要进一步了解最佳给药至分娩间隔、最佳使用的皮质类固醇、对多胎妊娠的影响以及确认对成年期的长期影响。